STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent.

New emergent PCI programs introduced in hospitals across the U.S. potentially cost billions to operate, yet do not improve access to these urgent services for most of the STEMI patients who need them, according to a study.

The FDA will review a Supplemental New Drug Application for the anticoagulant apixaban for the prevention of deep vein thrombosis in adults who undergo hip or knee replacement surgery.

A hospital and cardiology practice in Michigan will pay $4 million to settle a whistleblower lawsuit over allegedly unnecessary catheterizations.

This week’s news included a report about a technology developed by an interventional cardiologist that, based on its first-in-man report, effectively reduced radiation exposure to operators. Should we be skeptical of the results, considering the cardiologist holds the intellectual property to the shielding device and has licensed it to industry? We should be realistic.

Inspired by a genetic mutation that keeps low-density lipoprotein levels extremely low, three pharmaceutical companies are developing cholesterol drugs that mimic the trait. The New York Times described how drug makers are scurrying to get these potential blockbusters to market.

The Swiss pharmaceutical company Roche pulled the plug on a phase III clinical trial and all other trials involving the diabetes drug aleglitazar “due to safety signals and lack of efficacy.”

Amgen and Servier today announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease.